Veeva Vault QMS Validation Guide: GAMP 5 & CSA | GoVal

GoVal (Adventsys Technologies Pvt Ltd); Sundar Raman Sekar

Veeva Vault QMS Validation Guide: Risk Assessment, Configuration Testing, and Audit Trail Under CSA

How to validate Veeva Vault QMS in a regulated pharmaceutical environment using GAMP 5 Category 4 methodology, Veeva-supplied IQ/OQ packages, and FDA Computer Software Assurance (CSA) principles.

Written by: Sundar , Director, GoVal Published: June 22, 2026 Last updated: June 22, 2026

GAMP 5 Category 4 CSA · FDA Final Guidance 2025 21 CFR Part 11 EU Annex 11 eQMS / QMS Validation

Quick Answer

What GAMP 5 category is Veeva Vault QMS, and what does validation actually require?

Veeva Vault QMS is GAMP 5 Category 4 — Configured Software. Veeva Systems develops and maintains the base platform; your organisation configures it through the admin interface without writing custom code. Validation obligation centres entirely on your configuration — workflows, lifecycle states, role assignments, e-signature steps — not the underlying platform. Under FDA's CSA final guidance (September 2025), you can leverage Veeva's release-specific IQ and OQ documentation from ComplianceDocs to cover platform-level qualification, concentrating your own testing on PQ/UAT for configured GxP processes. Any custom Vault extensions built with the Vault Java SDK are elevated to Category 5 and require separate qualification.

How to Validate Veeva Vault QMS: Step-by-Step

6 steps from GxP scope definition through ongoing Vault release management — applying GAMP 5 Category 4 and CSA.

Step 1

Define GxP Scope and Classify Under GAMP 5

Not every Vault QMS process requires validation. Scope is determined by whether a process creates or modifies records required by a GxP predicate rule, or generates electronic signatures with regulatory significance.

In ScopeDeviations & Investigations

Records of quality events, root cause investigations, and closure decisions are GMP records under 21 CFR 211.192 and equivalent GxP regulations. Lifecycle configurations controlling approval routing and closure are in scope.

In ScopeCAPA Management

Corrective and preventive action records, effectiveness checks, and closure approvals are quality system records. Workflow configuration, e-signature steps, and notification rules for CAPA all require validation.

In ScopeChange Control

Change requests and impact assessments that authorise modifications to validated systems, manufacturing processes, or controlled documents are GMP-relevant. The approval workflow and electronic signature chain must be validated.

In ScopeComplaints & Audit Management

Product complaint records and internal audit findings are GMP records under 21 CFR 211.198 and ISO 13485. Lifecycle states, assignment rules, and closure approval configurations are in scope.

Typically Out of ScopeDashboard & Reporting Preferences

Personal dashboard layouts, saved filter configurations, and non-GxP reporting preferences have no record integrity impact and are excluded from validation scope with documented rationale.

Typically Out of ScopeNon-GxP Object Types

Administrative objects with no connection to product quality records — e.g., internal meeting requests or non-regulated project trackers — fall outside GxP validation scope.

GAMP 5 Classification for Veeva Vault QMS

Component	GAMP 5 Category	Validation approach
Standard Vault QMS platform	Category 4	Leverage Veeva IQ/OQ; own PQ/UAT for configured workflows
Customer-configured workflows, lifecycles, roles	Category 4	URS + FRA + PQ/UAT required for GxP-impacting configurations
Custom Vault SDK extensions (Java)	Category 5	FS, DS, code review, full IQ/OQ/PQ required
Vault platform infrastructure (Veeva-managed cloud)	Infra	Supplier qualification: SOC 2, ISO 27001, Veeva IQ documentation

Step 2

Leverage Veeva's Supplier IQ/OQ Package

This is where Veeva Vault QMS validation differs most from validating on-premise software. Veeva provides IQ and OQ documentation for every Vault release through ComplianceDocs, its customer-accessible validation portal. Under CSA, these are supplier testing artefacts that regulated companies can — and should — leverage rather than replacing with their own scripts.

The correct approach is not to ignore Veeva's package and write your own IQ/OQ from scratch. That duplicates effort Veeva has already performed and adds cost with no incremental compliance value. The correct approach is:

Download the release-specific IQ and OQ package from ComplianceDocs for your Vault version
Perform a supplier documentation review — assess whether the package covers the platform features relevant to your GxP-validated scope
Document a gap assessment identifying any GxP-relevant platform features not covered by Veeva's OQ test cases
Accept Veeva's test execution results as the IQ/OQ evidence; supplement with customer-executed scripts only for identified gaps
Perform a formal supplier qualification assessment documenting Veeva's SOC 2 Type II reports, ISO 27001 certification, and SDLC practices — this replaces the infrastructure IQ you would author for on-premise software

Under CSA: The FDA's final guidance explicitly supports leveraging supplier testing artefacts for Category 4 software. Your documented rationale — explaining why Veeva's IQ/OQ provides sufficient assurance for the platform layer — is the required output. The rationale must reference specific Veeva documentation versions and their coverage, not just assert that "vendor documentation was reviewed."

Step 3

Author URS and Perform Functional Risk Assessment

The URS for Vault QMS captures what your GxP-impacting configuration must do — written as testable requirements at the configuration level, not at the platform feature level.

Weak — describes the platform, not your configuration:

"The system shall support CAPA management."

Better — testable configuration requirement:

"When a CAPA record reaches the 'Effectiveness Check' lifecycle state, the system shall require an electronic signature from a user with the QA Manager security profile, display the meaning statement 'I confirm this CAPA has been effective', and prevent progression to 'Closed' until the signature is captured."

The Functional Risk Assessment scores each requirement for Severity, Occurrence, and Detectability. For Vault QMS, high-severity items typically include:

E-signature configurations for CAPA closure, deviation approval, and change control authorisation
Workflow routing rules controlling who can approve quality records at each lifecycle state
Access control configurations preventing users from modifying closed or approved quality records
Audit trail scope — which object types and field changes are captured in Vault's object record log

Lower-severity items — notification email triggers, dashboard report configurations, non-GxP object types — can be covered with a documented CSA rationale rather than scripted test cases.

Step 4

Execute PQ / UAT for Configured GxP Processes

Performance Qualification is where Vault QMS validation concentrates its testing effort. Veeva has tested the platform; you must test your configuration. PQ/UAT scenarios should exercise complete end-to-end GxP workflows as they will run in production.

Configuration Testing (OQ-level)

Tests that each GxP-impacting configuration behaves as specified in the URS under controlled conditions, including boundary and negative-path scenarios.

Deviation lifecycle: each state transition requires the configured approver role — attempt by incorrect role is blocked at the system level
CAPA e-signature: meaning statement displays correctly; incorrect password triggers authentication failure; audit trail entry created with user ID, timestamp, and signature reason
Change control: workflow routes to all configured approvers in the correct sequence; no step can be bypassed
Access controls: negative-path testing — security profiles deny access to object types and actions outside their permission set
Audit trail: field-level changes to GxP object records are captured with before/after values in the object record log

End-to-End PQ / UAT Scenarios

Complete process flows executed by actual process owners in the validated environment using representative data.

Manufacturing deviation: event capture → investigation assignment → root cause → CAPA link → QA approval → closure with e-signature
CAPA lifecycle: initiation → action assignment → implementation → effectiveness check → QA closure approval
Change control: request → impact assessment → multi-level approval chain → implementation → post-change review
Supplier audit: audit plan → finding capture → CAPA generation from finding → closure verification
Product complaint: intake → investigation → regulatory reportability decision → closure with e-signature

Step 5

Validate Audit Trail Coverage for 21 CFR Part 11

Vault maintains three separate audit logs. All three are relevant to GxP compliance and all three must be reviewed as part of audit trail validation.

Audit Log Type What it captures GxP validation requirement

Document Audit Trail Every action on a document — view, download, edit, approve, e-sign, version change, lifecycle transition. User, timestamp, action type all captured. Test that GxP-relevant document actions generate complete entries. Confirm read-only access — no user can alter or delete entries.

Object Record Audit Trail Field-level changes to Vault object records (deviations, CAPAs, change controls). Captures who changed which field, from what value to what value, and when. Test that before/after values are captured for GxP-relevant fields. Verify the audit trail cannot be disabled for in-scope object types.

Configuration Audit Trail Admin-level changes — security profile modifications, lifecycle state changes, workflow edits, user role assignments. Confirm configuration changes post-go-live are captured and reviewable. This log must be part of periodic review — undocumented config changes are a common inspection finding.

Key point: E-signature steps in Vault must be configured to require re-authentication (username and password) and display a meaning statement at the point of signing. Inspectors specifically verify that meaning statements are Vault-enforced — not just a procedural instruction in a SOP — and that the signed record links permanently to the signature event in the audit trail.

Step 6

Establish Change Control for Vault Releases

Veeva releases Vault updates approximately three times per year on a published schedule. Each release is a change event that requires formal assessment in a validated GxP environment before the release is accepted in your production Vault.

For Each Vault Release

Download the updated IQ/OQ package from ComplianceDocs for the new release version
Review Veeva's release notes — identify changes to features used in your GxP-validated configuration
Perform a formal release impact assessment against your Configuration Specification baseline
Gap-assess the new IQ/OQ package against the previous version; accept or supplement as needed
Test the release in Veeva's provided sandbox environment before production deployment
Execute risk-based regression PQ on configured workflows affected by the release changes
Obtain QA sign-off and update the Validation Summary Report before the release is promoted to production

For Configuration Changes

Any change to a GxP-impacting workflow, lifecycle, role assignment, or e-signature step requires a documented change request
Perform a change impact assessment against the validated URS and Configuration Specification
Test the changed configuration in the non-production Vault environment before promoting to production
Vault's configuration audit trail captures admin-level changes — reference it in the change control record rather than recreating it separately
Update the Configuration Specification to reflect the new validated baseline after every approved change

Periodic review — at least annually — confirms that the Configuration Specification reflects actual Vault settings, access controls are current, and no undocumented configuration drift has occurred since the last validated state was confirmed.

Common Inspection Findings for Veeva Vault QMS

These patterns appear in FDA 483 observations and EMA inspection reports for pharmaceutical companies using cloud-based eQMS platforms including Veeva Vault.

E-signature meaning statements not enforced at the system level. Inspectors verify that meaning statements appear within the Vault signature step itself — not just in a surrounding SOP. If the Vault configuration does not enforce a specific meaning statement string at each GxP e-signature point, Part 11 §11.50 is not satisfied regardless of what the SOP says.
Configuration audit trail not reviewed as part of post-go-live validation maintenance. Admin-level changes to Vault workflows, lifecycles, and security profiles after initial go-live are captured in the configuration audit log — but many validation programmes do not include this log in periodic reviews. Undocumented configuration changes discovered during an inspection are treated as change control failures.
PQ test scripts test Veeva platform features, not customer configurations. Test scripts that simply verify "CAPA records can be created and closed" are testing a Veeva platform feature that Veeva has already qualified. Inspectors look for evidence that your specific approval routing, role restrictions, and e-signature requirements were tested — not the generic Vault CAPA capability.
Vault release impact assessments performed after production deployment. Veeva publishes release schedules well in advance. Impact assessments and regression testing must be completed — and QA sign-off obtained — before the production Vault accepts the new release. Post-deployment discovery of affected validated functionality is a change control failure.
Access control testing limited to positive-path scenarios only. Testing that a QA Manager can approve a CAPA is positive-path. Inspectors also expect negative-path evidence: that a user without the QA Manager role is denied the approval action at the system level. Absence of negative-path access control testing is a consistent finding.

Frequently Asked Questions

What GAMP 5 category is Veeva Vault QMS?

Veeva Vault QMS is GAMP 5 Category 4 — Configured Software. Veeva Systems develops and maintains the base platform; regulated companies configure it through a constrained admin interface without writing custom code. Validation obligation centres on your specific configuration — workflows, lifecycle states, role assignments, e-signature requirements — not Veeva's software engineering process. Custom Vault extensions built with the Vault Java SDK are Category 5 and require separate qualification with Functional Specification, Design Specification, and code review.

Does Veeva provide IQ and OQ documentation for Vault QMS, and can we use it?

Yes. Veeva publishes IQ and OQ documentation for each Vault release through ComplianceDocs, its customer-facing validation portal. Under CSA, you can leverage these as supplier testing artefacts for the platform layer, reducing or eliminating customer-authored IQ/OQ scripts for base platform features. Your obligation becomes: downloading the package, performing a formal gap assessment to confirm it covers your GxP-relevant Vault features, documenting your acceptance rationale, and then concentrating your own testing effort on PQ/UAT for your specific GxP-configured workflows.

What configuration testing is required for Veeva Vault QMS in pharma?

Configuration testing must cover: CAPA and deviation workflow routing to confirm correct approvers at each lifecycle state; e-signature step triggers and meaning statement display at the point of signing; role-based access controls confirming each security profile is permitted and denied the correct actions; notification rules firing at configured lifecycle transitions; and integration data flows if Vault connects to SAP, MES, or LIMS. Standard platform features that Veeva has already tested in their OQ package — basic record creation, standard Vault navigation — do not require customer scripted testing under CSA. The exclusion rationale must be documented.

How do you handle Veeva Vault releases in a validated GxP environment?

Veeva releases Vault updates approximately three times per year on a fixed published schedule. Each release requires a documented impact assessment before production deployment. Review Veeva's release notes for changes to features used in your GxP-validated configuration. Obtain the updated IQ/OQ package from ComplianceDocs and gap-assess it against the previous version. Test the release in Veeva's sandbox before production. Execute risk-based regression PQ on configured workflows affected by the release. QA sign-off is required before accepting the release in production — impact assessments performed after deployment are a change control finding.

Does Veeva Vault QMS automatically satisfy 21 CFR Part 11?

No — Veeva provides the technical controls required by Part 11 (audit trails, e-signatures, access controls), but compliance is not automatic. You must configure and validate these controls for your specific GxP processes. The three Vault audit log types — document, object record, and configuration — must all be tested to confirm they capture the required data for each GxP record in scope. E-signature steps must be explicitly configured to require authentication and display meaning statements at point of signing. These configurations must be tested in PQ and the configuration audit trail must be included in periodic reviews to catch post-go-live admin changes.

What is the difference between validating Vault QMS vs Vault QualityDocs?

Vault QMS manages quality processes — deviations, CAPA, change control, audits, complaints. Vault QualityDocs manages controlled documents — SOPs, work instructions, validation records. Both are GAMP 5 Category 4 on the same Vault Platform. If your organisation uses both, you need separate URS and PQ protocols for each application's GxP processes, but you can share a single platform IQ/OQ package review and a single Validation Plan. Many organisations validate both in the same project with separate OQ/PQ protocol sections per application.

What are common validation failures found during Veeva Vault QMS inspections?

The five most common findings are: (1) e-signature meaning statements not enforced at the Vault configuration level — only described in an SOP; (2) configuration audit log not reviewed as part of periodic review, leaving undocumented admin changes undetected; (3) PQ scripts testing Veeva platform features rather than the customer's actual configured workflows and role restrictions; (4) Vault release impact assessments completed after production deployment; and (5) access control testing limited to positive-path only — no negative-path evidence that incorrect roles are denied access at the system level.